Health Economics and Outcomes Research (HEOR) Market: Industry Outlook, Growth Forecast, and Competitive Analysis (2025–2034)

The global Health Economics and Outcomes Research (HEOR) market is becoming an indispensable part of modern healthcare decision-making. As governments, insurers, and healthcare providers increasingly focus on the cost-effectiveness, clinical outcomes, and patient-centric care, HEOR plays a pivotal role in shaping strategies around drug pricing, reimbursement, and regulatory approvals.

In 2024, the HEOR market share reached a valuation of USD 1.50 billion, driven by the rise in mergers and acquisitions among major players, efforts to streamline healthcare spending, and the growing demand for real-world evidence (RWE). The market is expected to grow at a CAGR of 13.50% from 2025 to 2034, reaching USD 5.32 billion by 2034.

This article offers a detailed analysis of the HEOR market, covering key trends, drivers, opportunities, challenges, and leading players shaping the future of the industry.

Health Economics and Outcomes Research (HEOR) Market Overview

HEOR is a specialized discipline that evaluates the economic, clinical, and humanistic outcomes of healthcare interventions. It supports healthcare stakeholders—including payers, providers, regulatory bodies, and pharmaceutical companies—by offering actionable insights for reimbursement policies, formulary placements, and product value demonstration.

Key areas within HEOR include:

• Cost-Effectiveness Analysis (CEA)

• Budget Impact Analysis (BIA)

• Quality Adjusted Life Years (QALYs)

• Patient-Reported Outcomes (PROs)

• Real-World Data (RWD) and Real-World Evidence (RWE)

HEOR supports evidence-based healthcare policies and enhances the ability of companies to demonstrate product value beyond clinical trial results.

Global Market Size and Share

• 2024 Market Size: USD 1.50 Billion

• Forecast CAGR (2025–2034): 13.50%

• 2034 Projected Market Size: USD 5.32 Billion

North America dominates the global HEOR market, owing to a well-established healthcare infrastructure, high R&D investment, and favorable regulatory environments. Europe follows closely, with increasing emphasis on value-based healthcare. Meanwhile, the Asia-Pacific region is witnessing a surge in demand due to increasing drug approvals, clinical trial activity, and healthcare reforms.

For more information about this report visit

Market Dynamics and Emerging Trends

Market Drivers

• Value-Based Healthcare Models: Growing shift from volume to value-based models requires economic evaluations and outcome measurements.

• Rising R&D Expenditure: Pharma and biotech companies rely on HEOR to justify pricing and market access strategies.

• Mergers and Acquisitions: Industry consolidation is helping companies expand HEOR capabilities and global presence.

• Regulatory Emphasis on RWE: Health authorities such as the FDA and EMA increasingly demand RWE for approval and post-market surveillance.

• Growth in Specialty and Orphan Drugs: High-cost treatments require cost-utility justifications, boosting demand for HEOR services.

Market Restraints

• Data Privacy and Security Issues: Working with real-world health data poses compliance risks, especially in regions with strict privacy laws.

• Shortage of Skilled Professionals: Lack of trained HEOR experts hampers service quality and project timelines.

• Variability in Data Sources: Inconsistent quality and format of RWD may affect the accuracy of outcome assessments.

• Complexity in Standardization: Differences in healthcare systems globally pose challenges in standardizing HEOR practices.

Emerging Trends

• Artificial Intelligence and Machine Learning in HEOR: AI-driven models help derive actionable insights from vast RWD sets.

• Decentralized Clinical Trials Integration: Real-time data from decentralized trials is increasingly integrated into HEOR frameworks.

• Patient-Centric Outcomes: Growing focus on PROs and patient engagement in outcomes research.

• Use of Blockchain for Data Integrity: Ensures security and traceability of healthcare data used in economic analysis.

Growth Outlook for the HEOR Market

The HEOR market is experiencing rapid expansion, with a growing emphasis on personalized medicine, outcomes-based reimbursement, and population health management. This growth is further supported by:

• Greater global collaboration on healthcare cost containment

• Pharmaceutical companies facing increased pressure for market access justification

• Inclusion of HEOR early in the drug development process

• Expansion of CRO partnerships for outsourced HEOR projects

As healthcare stakeholders demand more transparency and measurable value, HEOR will continue to evolve as a core function within healthcare systems and life sciences companies.

Opportunities and Challenges in the HEOR Market

Opportunities

• Emerging Markets Expansion: Growth in healthcare infrastructure and government initiatives in APAC, Latin America, and Middle East regions.

• Integration with Health Technology Assessment (HTA): Strong opportunity to align HEOR with HTA agencies for faster product adoption.

• Digitization of Healthcare Systems: Enhanced EHR adoption and data lakes provide more accessible, reliable data for HEOR modeling.

• Growth in Biosimilars and Generics: HEOR provides comparative studies to support cost-effectiveness and payer adoption.

• Collaborative Research Models: Partnerships between academia, pharma, and regulatory bodies offer fertile ground for HEOR development.

Challenges

• Regulatory Heterogeneity: Varying regional requirements for economic evaluation and RWE.

• Inconsistent Outcome Measures: Lack of uniform patient-reported outcome standards can hinder cross-comparison.

• Complexity of Multi-Stakeholder Engagement: Aligning interests across regulators, payers, providers, and patients remains a hurdle.

• Ethical Considerations in Data Use: Consent, bias, and fairness must be addressed when using patient-centric data in HEOR studies.

Recent Developments in the HEOR Market

• McKesson Corporation expanded its real-world evidence and HEOR offerings through collaborations with healthcare providers and payers.

• Axtria enhanced its cloud-native data analytics solutions for life sciences companies to integrate commercial analytics with HEOR data.

• IQVIA launched advanced HEOR consulting services focused on oncology and rare diseases with a robust RWD ecosystem.

• Cytel released machine learning-based tools for probabilistic modeling to improve forecasting in health economic evaluations.

• ZS partnered with global pharma firms to embed HEOR into market access and launch excellence strategies.

• Deloitte introduced its ConvergeHEALTH platform for real-world analytics supporting outcomes measurement.

These advancements reflect the technology integration and strategic investments being made to position HEOR at the center of healthcare innovation.

Competitive Landscape and Key Player Analysis

The global HEOR market is moderately fragmented, with established players offering a combination of consulting, data analytics, and real-world evidence generation services.

McKesson Corporation

A leader in healthcare services, McKesson provides HEOR insights tied to its vast data networks and pharmacy benefit solutions.

Axtria

Offers cloud-based platforms that integrate HEOR, commercial analytics, and medical affairs to drive value demonstration and payer engagement.

Cardinal Health

Delivers evidence generation services with a focus on clinical value analysis, comparative effectiveness, and cost modeling.

Avalon Health Economics

A boutique HEOR consultancy offering robust services in cost-effectiveness analysis, economic modeling, and policy advisory.

Medlior

Provides HEOR and RWE services across Canada and globally, with a specialty in economic modeling and database analytics.

IQVIA

A global leader in healthcare data, IQVIA combines its RWD assets with advanced HEOR and health technology assessment (HTA) solutions.

Pharmalex GmbH

Offers integrated services in regulatory affairs, pharmacovigilance, and HEOR, especially in European markets.

ZS

Helps life sciences clients embed HEOR into product development and commercialization strategies using advanced analytics.

Deloitte

Delivers strategic HEOR consulting alongside digital transformation services for pharma and medtech clients.

Cytel

Specializes in statistical modeling, economic simulations, and Bayesian approaches to HEOR for drug development and regulatory support.

These players are actively shaping the future of HEOR by emphasizing data integrity, patient-centricity, and AI-driven analytics.

Frequently Asked Questions (FAQs)

What is HEOR?
Health Economics and Outcomes Research (HEOR) evaluates the economic and patient outcome impacts of healthcare interventions to support reimbursement, pricing, and policy decisions.

What was the value of the global HEOR market in 2024?
The market was valued at USD 1.50 billion in 2024.

What is the projected size of the HEOR market by 2034?
It is expected to grow to USD 5.32 billion by 2034.

Which region dominates the HEOR market?
North America leads the global HEOR market, followed by Europe and Asia-Pacific.

Why is HEOR important in healthcare?
HEOR supports evidence-based healthcare by evaluating cost-effectiveness, improving market access, and guiding pricing and reimbursement strategies.

Who are the key players in the HEOR market?
Major players include McKesson, Axtria, IQVIA, Deloitte, ZS, Pharmalex, Cytel, and Cardinal Health.

What are the main applications of HEOR?
Applications include drug pricing, market access, clinical guidelines, HTA submissions, and healthcare policy development.

What are the future trends in HEOR?
The market is trending toward AI integration, patient-centric outcomes, decentralized data sourcing, and global standardization.

The Health Economics and Outcomes Research (HEOR) market is becoming a cornerstone of evidence-based, value-driven healthcare systems. From informing regulatory approvals and payer decisions to guiding clinical pathways and policy frameworks, HEOR helps quantify the real-world value of medical interventions.

With an expected rise from USD 1.50 billion in 2024 to USD 5.32 billion by 2034, HEOR presents massive opportunities for healthcare innovators, data scientists, economists, and policy-makers. As healthcare moves toward personalization, digital transformation, and value optimization, HEOR will play a leading role in shaping the global healthcare economy.

Find More Blog:

CDMO Market growth

Liver Fibrosis Drug Pipeline Analysis share

Juvenile Macular Degeneration (JMD) Drug Pipeline Analysis trend